0001209191-22-023862.txt : 20220408 0001209191-22-023862.hdr.sgml : 20220408 20220408162627 ACCESSION NUMBER: 0001209191-22-023862 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220406 FILED AS OF DATE: 20220408 DATE AS OF CHANGE: 20220408 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PRASAD SUYASH CENTRAL INDEX KEY: 0001679129 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 22817325 MAIL ADDRESS: STREET 1: C/O AUDENTES THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY ST., SUITE 2650 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-06 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001679129 PRASAD SUYASH C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, STE 1430 DALLAS TX 75247 0 1 0 0 CMO and Head of R&D Employee Stock Option (right to buy) 6.52 2022-04-06 4 A 0 40325 0.00 A 2032-04-06 Common Stock 40325 40325 D 25% of the total number of shares underlying the option shall vest and become exercisable on April 6, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Kamran Alam, Attorney-in-Fact 2022-04-08